BioSpace News Archive

IPA Announces Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology

- Phesgo™ Can be Administered in 5 to 8 Minutes Compared with Hours for the Standard Sequential IV Administration of Perjeta® and Herceptin® - - First Subcutaneous Fixed-dose Combination of Two Monoclonal Antibodies Approved Utilizing Halozyme’s ENHANZE® Technology - - Data Showed That 85% of Patients Preferred Phesgo™ Compared to Standard Intravenous Administration -

A new study published today in Blood , the official journal of the American Society of Hematology, sheds light on the mysterious blood clots and inflammation in patients with Novel Coronavirus (COVID-19). The peer-reviewed paper describes a new medicine that may block COVID-19 inflammation being developed by PEEL Therapeutics, a

ReNeuron Group plc (AIM:RENE), a global leader in the development of cell-based therapeutics, is pleased to announce further positive long-term data from the ongoing Phase 2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP)

North Sur Resources Inc. and Mindset Pharma Inc. are pleased to announce that they have signed a binding letter of intent to combine their corporate entities.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President, Chief Accounting Officer.

Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal year 2020 ended March 31, 2020.

Predictive Oncology Inc. (the “Company,” “Predictive Oncology,” “we,” “our” or “us”) (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced transaction resulting in gross cash proceeds to the Company of approximately $2.2 million

OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the benefits of its OmniSeq Advance® comprehensive genomic and immune profiling assay to detect the presence of rare alterations in the RET gene in the tumors of some patients with non-small cell lung cancer (NSCLC) and thyroid cancer

GoLiver Therapeutics, a start-up focused on the development of Innovative Therapy Medicines, in particular cell therapy products for life-threatening liver diseases without the need for transplant using differentiated pluripotent stem cells, announces that the European Medicines Agency (E